Sixty one patients with a significant disturbance of tolerance to the thyroid antigens in the absence of disturbance of the thyroid function were involved in the research. Twenty two patients with chronic hepatitis C, genotype 1 HCV, receiving antiviral therapy, were also included in the research. Patients were immunized intracutaneously with autoleukocytes for autoimmune process inhibition. After single immunization with autoleukocytes decrease in the level of antibodies against the thyroid antigens was observed in all patients. In some patients without chronic hepatitis C the levels of thyroperoxidase and thyroglobulin antibodies decreased by 50% and more (33.33% and 20.51%, respectively). In patients with ChHC these indices were considerably lower, and the duration of the achieved effect was shorter. However, immunization inhibited activity of immune process in patients with ChHC due to interferon therapy. The suggested method enables to decrease the threat for thyroiditis development even in patients with chronic hepatitis C during antiviral therapy.

Influence on pro- and anti-inflammatory cytokines of an ill person is an urgent aspect of treatment of many diseases. For inhibition of synthesis of a high level of pro-inflammatory cytokines, medications which are recombinant monoclonal antibodies, especially to tumour necrosis factor α (TNF-α), are used. However, these methods of treatment require further improvement by elaborating new approaches with a wider spectrum of influence on the immune system.A completely new method of reduction in high activity of TN F-α with the method of intradermal autoleukocyte immunization is presented in the article. Investigation was performed in a group of patients with psoriasis (24) with a high level of TNF-α in the blood (over 30 pg/ml). Simultaneously such investigation was performed on patients with psoriasis (9) without TNF-α detected (0 pg/ml).As a result of immunization, a significant reduction in TNF-α occurred in all patients with its high level, in 16 (66.7%) from 24 patients – to 0-5 pg/ml. The level of reduction and duration of the achieved effect was of an individual character and requires further investigation. However, the achieved results prove the expediency of administration of this immunization method for patients requiring reduction of TNF-α synthesis.However, the content of TNF-α in blood serum could not be detected in most patients with a low level of cytokine (in 6 from 9) after immunization (as well as before immunization), but an increase in its level from 0 to 5-8 pg/ml was observed in 3 patients. On the basis of the conducted research, the authors suggest that the influence of immunization on cytokine synthesis depends on the condition of immune cells and correlation of pro- and anti-inflammatory cytokines in a patient's skin.

The co-author of the Ministry of Health of Ukraine Protocol "Providing Health Care for Coronavirus Disease 2019 Treatment" aimed to combat COVID-19 presented the preconditions of its creation. Ukraine was faced with COVID-19 at the start of its reforms to the secondary stage of medical care. In addition, there were no regulative documents in the country that would allow doctors to prescribe treatment to patients with COVID-19 using drugs that proved their eff ectiveness. Since there still no offi cial recommendations in the world concerning the use of drugs to treat COVID-19 that would be grounded on the evidence-based medicine (such evidence will be obtained at a later stage as data is analyzed), the entire world is now using these treatments as part of clinical trials only. According to WHO, such experimental treatment is now being carried out using over 230 diff erent means, including immunobiological drugs, while in the USA, "Extended access to compassionate use" program was approved by the US Food and Drug Administration (FDA).The Law of Ukraine "On Amending Some Legislative Acts of Ukraine Aimed at Preventing the Occurrence and Spread of Coronavirus Disease (COVID-19)" states that " coronavirus disease (COVID-19) treatment and/or prevention methods may be used to treat patients with coronavirus disease (COVID-19) confi rmed by the laboratory testing if such coronavirus disease (COVID-19) prevention practices and/or treatment are allowed by the offi cial bodies of the USA, European